“Acute Ischemic Stroke Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Ischemic Stroke Market.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Acute Ischemic Stroke Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Acute Ischemic Stroke and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Ischemic Stroke market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Acute Ischemic Stroke Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Ischemic Stroke Therapeutic Segment @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight
Acute Ischemic Stroke Therapeutics Landscape
There are approx. 35+ key Acute Ischemic Stroke companies which are developing Acute Ischemic Stroke therapies. Currently, GNT Pharma is leading the therapeutics market with its Acute Ischemic Stroke drug candidates in the most advanced stage of clinical development.
The Leading Players in the Acute Ischemic Stroke Therapeutics Market Include:
AbbVie, Acticor Biotech, Angde Biotech Pharmaceutical, aptaTargets, Athersys|Healios K.K., Bayer, Biogen, Biogen Inc., Bristol-Myers Squibb, Clinuvel Pharmaceuticals, DiaMedica Therapeutics, Genentech, Inc., GNT Pharma, Healios, Janssen Pharmaceutical, JCR Pharmaceuticals, Lumosa Therapeutics, NC Medical Research, NoNO Inc., NuvOx Pharma, Pharmazz, Pharming Group, PT. Prodia Stem Cell Indonesia, Revalesio Corporation, Roche, Shin Poong Pharmaceutical, Shionogi & Co., Ltd., Silver Creek Pharmaceuticals, Supergene, Tasly Pharmaceutical, TrueBinding, Inc, ZZ Biotech, and others.
Acute Ischemic Stroke Emerging and Marketed Drugs Covered in the Report Include:
BMS-986177/milvexian: Bristol Myers Squibb Company/Janssen Pharmaceuticals
DM199: DiaMedica Therapeutics
Glenzocimab: Acticor Biotech
Invimestrocel: Healios/Athersys
LT3001: Lumosa Therapeutics
Nelonemdaz: GNT Pharma
Nerinetide: NoNO Inc.
SP-8203: Shin Poong Pharmaceutical
Tenecteplase: Genentech
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Acute Ischemic Stroke Current Treatment Patterns
4. Acute Ischemic Stroke – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acute Ischemic Stroke Late Stage Products (Phase-III)
7. Acute Ischemic Stroke Mid-Stage Products (Phase-II)
8. Acute Ischemic Stroke Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Ischemic Stroke Discontinued Products
13. Acute Ischemic Stroke Product Profiles
14. Key Companies in the Acute Ischemic Stroke Market
15. Key Products in the Acute Ischemic Stroke Therapeutics Segment
16. Dormant and Discontinued Products
17. Acute Ischemic Stroke Unmet Needs
18. Acute Ischemic Stroke Future Perspectives
19. Acute Ischemic Stroke Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
